Alnylam Pharmaceuticals, Inc. and Genzyme Corporation Enters into Amendment No. 2 to the Master Collaboration Agreement
January 08, 2018 at 07:03 am
Share
On January 6, 2018, Alnylam Pharmaceuticals, Inc. and Genzyme Corporation entered into amendment no. 2 (the collaboration amendment) to the Master Collaboration agreement dated as of January 11, 2014 (the Original collaboration agreement), as amended by amendment no. 1 to the Master collaboration agreement dated July 1, 2015 (amendment No. 1). In connection and simultaneously with entering into the collaboration amendment, the company and Genzyme also entered into the ALN-AT3 Global License Terms with respect to ALN-AT3 (fitusiran) and any back-up products (the “AT3 License Terms”) and an exclusive license agreement with respect to all TTR products, including ALN-TTR02 (patisiran), ALN-TTRsc02 (a subcutaneously administered investigational RNAi therapeutic in clinical development) and any back-up products (the “Exclusive TTR License”). The collaboration amendment, together with the AT3 License Terms and the Exclusive TTR License, revise the terms and conditions of the Master Agreement to provide the company the exclusive right to pursue the further global development and commercialization of all TTR products, including ALN-TTR02 (patisiran), ALN-TTRsc02 and any back-up products, provide Genzyme the exclusive right to pursue the further global development and commercialization of ALN-AT3 (fitusiran) and any back-up products and terminate the previous co-development and co-commercialization rights related to ALN-TTRsc, ALN-TTRsc02 and ALN-AT3 (fitusiran) under the Master Agreement. Going forward, the Company will fund all development and commercialization costs for ALN-TTR02 (patisiran) and ALN-TTRsc02.
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
ALNYLAM PHARMACEUTICALS, INC. 
